AVROBIO, Inc. (AVRO): Price and Financial Metrics
GET POWR RATINGS... FREE!
AVRO Stock Price Chart Interactive Chart >
AVRO Price/Volume Stats
| Current price | $0.91 | 52-week high | $1.90 |
| Prev. close | $0.93 | 52-week low | $0.56 |
| Day low | $0.86 | Volume | 420,000 |
| Day high | $0.93 | Avg. volume | 331,862 |
| 50-day MA | $0.84 | Dividend yield | N/A |
| 200-day MA | $0.86 | Market Cap | 39.83M |
AVROBIO, Inc. (AVRO) Company Bio
AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. It lead product candidate in AVR-RD-01, which is in Phase 1 clinical trial for the treatment of Fabry disease. The company is also developing AVR-RD-02 for the treatment of Gaucher disease; AVR-RD-03 for the treatment of Pompe disease; and AVR-RD-04 for the treatment of cystinosis. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Latest AVRO News From Around the Web
Below are the latest news stories about AVROBIO INC that investors may wish to consider to help them evaluate AVRO as an investment opportunity.
AVROBIO Inc. (AVRO) can beat the pack with these strategiesIn Monday’s session, AVROBIO Inc. (NASDAQ:AVRO) marked $0.85 per share, up from $0.85 in the previous session. While AVROBIO Inc. has overperformed by 0.02%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AVRO fell by -61.88%, with highs and lows ranging from $2.28 to $0.56, whereas […] |
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., January 05, 2023--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 7,500 restricted stock units (RSUs) to one new employee as an inducement award under the company’s 2019 Inducement Plan. The grant was made in accordance with Nasdaq Listing Rule 5635(c)(4). |
A stock that deserves closer examination: AVROBIO Inc. (AVRO)As of Tuesday, AVROBIO Inc.’s (NASDAQ:AVRO) stock closed at $0.79, up from $0.77 the previous day. While AVROBIO Inc. has overperformed by 2.42%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AVRO fell by -80.05%, with highs and lows ranging from $4.15 to $0.56, whereas the […] |
Analysts Say AVROBIO Inc. (NASDAQ:AVRO) Can Really Get To $6.00 In 12 MonthsIn last trading session, AVROBIO Inc. (NASDAQ:AVRO) saw 0.55 million shares changing hands with its beta currently measuring 1.67. Company’s recent per share price level of $0.76 trading at -$0.03 or -3.67% at ring of the bell on the day assigns it a market valuation of $33.23M. That closing price of AVRO’s stock is at … Analysts Say AVROBIO Inc. (NASDAQ:AVRO) Can Really Get To $6.00 In 12 Months Read More » |
AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene TherapyCAMBRIDGE, Mass., December 07, 2022--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced new interim pharmacokinetic, pharmacodynamic and clinical efficacy data, showing stabilization or reversal of multiple clinically relevant measures in five patients with Gaucher disease after they received a single dose of AVR-RD-02, an investigational hematopoietic stem cell (HSC) gene therapy. In addition, fo |
AVRO Price Returns
| 1-mo | 7.08% |
| 3-mo | 39.87% |
| 6-mo | -12.50% |
| 1-year | -49.72% |
| 3-year | -96.19% |
| 5-year | N/A |
| YTD | 27.65% |
| 2022 | -81.48% |
| 2021 | -72.38% |
| 2020 | -30.75% |
| 2019 | 20.90% |
| 2018 | N/A |
Loading social stream, please wait...